$1.94-0.05 (-2.51%)
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer.
Tempest Therapeutics, Inc. in the Healthcare sector is trading at $1.94. The stock is currently near its 52-week low of $1.50, remaining 64.5% below its 200-day moving average. Technical signals show neutral RSI of 59 and bullish MACD crossover, explaining why TPST maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome prolifer...